0001225208-20-011150.txt : 20200901
0001225208-20-011150.hdr.sgml : 20200901
20200901202630
ACCESSION NUMBER: 0001225208-20-011150
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200828
FILED AS OF DATE: 20200901
DATE AS OF CHANGE: 20200901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BAKER G LEONARD JR
CENTRAL INDEX KEY: 0001201715
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 201155504
MAIL ADDRESS:
STREET 1: 755 PAGE MILL ROAD, SUITE A-200
CITY: PALO ALTO
STATE: CA
ZIP: 94304-1005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
doc4.xml
X0306
4
2020-08-28
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001201715
BAKER G LEONARD JR
755 PAGE MILL ROAD, SUITE A-200
PALO ALTO
CA
94304-1005
1
Common Stock
2020-08-28
4
P
0
20444.0000
12.4835
A
3135237.0000
I
By Ltd Partnership
Common Stock
2020-09-01
4
P
0
25807.0000
12.4976
A
3161044.0000
I
By Ltd Partnership
Common Stock
996838.0000
D
Common Stock
955055.0000
I
By Trust
The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person, to the extent of the reporting person's pecuniary interest therein, at prices ranging from $15.76 to $15.7602, inclusive, on May 28, 2020. The reporting person has agreed to pay to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.43 to $12.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.45 to $12.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.
Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.
cortglbnew.txt
/s/ Kanwalpreet S. Kalra, by power of attorney
2020-09-01
EX-24
2
cortglbnew.txt
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby authorizes
Christopher J. Basso or Kanwalpreet S. Kalra to execute for and on behalf
of the undersigned Forms 3, 4, and 5, and any Amendments thereto for Corcept
Therapeutics, Inc. (the "Company"), and cause such form(s) to be filed with
the United States Securities and Exchange Commission pursuant to Section
16(a) of the Securities Act of 1934, relating to the undersigned's beneficial
ownership of securities in the Company. The undersigned hereby grants to
each such attorney-in-fact full power and authority to do and perform any
and every act and thing whatsoever requisite, necessary, or proper to be
done in the exercise of any of the rights and powers herein granted, as
fully to all intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such attorney-
in-fact's substitute or substitutes, shall lawfully do or cause to be done
by virtue of this power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in serving
in such a capacity at the request of the undersigned, are not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4, and 5 with respect
to the undersigned's holdings of, and transactions in, securities issued by
the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
In witness whereof, the undersigned has caused this Power of Attorney
to be executed as of this 28th day of August, 2020.
/s/ G. Leonard Baker, Jr.